Work

Abstract A114: Micvotabart pelidotin, an ADC targeting non-cellular EDB+FN, induces an immune response in tumors from participants in a phase 1 dose escalation study

Year: 2025

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-a114

Authors: Eugene Lurie, Sara Lewandowski, Justin Trickett, Krystal Watkins, Anthony W. Tolcher, Katherine Clifton, Benedito A. Carneiro, Jason T. Henry, Shiraj Shen, Nuria Kotecki, Sylvie Rottey, Rachel Galot, Hongwei Wang, Marsha Crochiere

Institutions: Washington University in St. Louis, Brown University, HealthONE, Institut Jules Bordet, Ghent University Hospital, Ghent University, Cliniques Universitaires Saint-Luc

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415455877

Cites:

Cited by:

Related to: